Likewise, surprisingly, for pBMSCs treated with OM + BMP-2, osteogenic differentiation even tended to be improved under the inhibition of TGF-β and BMP signaling compared to those with no inhibitor used (Figure 4B, Table S3). The gene discussed is BMP2; the disease is ocular melanoma.